



## Immuron filed XBRL data with the SEC

**Melbourne, Australia, November 3, 2021:** Immuron Limited (ASX: IMC; NASDAQ: IMRN) ("Immuron" or the "Company"), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut-mediated pathogens, advises that, the Company is required by the Securities and Exchange Commission (SEC) to provide the Company's financial statements in an interactive data format using eXtensible Business Reporting Language (XBRL).

The purpose of this release is to advise that further to the Form 20-F filing as announced on 29 October 2021, the Company has also filed the XBRL interactive data with the SEC, which is available via the company website at <https://www.immuron.com.au/corporate-directory-and-governance/>.

This release has been authorised by the directors of Immuron Limited.

- - - END - - -

### COMPANY CONTACT:

**Dr Jerry Kanellos, Ph.D.**  
Chief Executive Officer  
Ph: +61 (0)3 9824 5254  
[info@immuron.com](mailto:info@immuron.com)